Tech Company Financing Transactions
Cygnal Therapeutics Funding Round
On 10/9/2019, Cygnal Therapeutics raised funding from Flagship Pioneering.
Transaction Overview
Company Name
Announced On
10/9/2019
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Flagship Pioneering (Noubar Afeyan)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
325 Vassar St. 2B
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pearl Huang
Founder
Noubar Afeyan
Founder
Avak Kahvejian
Founder
Jordi Mata-Fink
Vice President
Daniel Blom
Vice President
Hongyue Dai
Vice President
Jonathan Hurov
Vice President
Grazia Piizzi
VP - Finance
Pauline McGowan
Browse more venture capital transactions:
Prev: 10/9/2019: Razberi venture capital transaction
Next: 10/10/2019: Mynosys Cellular Devices venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs